What glucagon does in retatrutide is central to understanding why this investigational triple receptor agonist may represent a significant advance in metabolic medicine. Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — a combination not seen in any currently licensed UK medicine. Whilst glucagon is traditionally associated with raising blood glucose, its role in retatrutide is carefully balanced by the insulin-stimulating effects of GLP-1 and GIP, with the aim of harnessing glucagon's metabolic properties — including potential increases in energy expenditure and hepatic fat reduction — without causing harmful hyperglycaemia. Retatrutide remains under clinical investigation and is not yet approved by the MHRA or EMA.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
